Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Travera Inc
Turning Point Therapeutics, Inc.
Eastern Cooperative Oncology Group
City of Hope Medical Center
Kaiser Permanente
Washington University School of Medicine
City of Hope Medical Center
University of Nebraska
Eli Lilly and Company
Var2 Pharmaceuticals
Memorial Sloan Kettering Cancer Center
UNC Lineberger Comprehensive Cancer Center
Washington University School of Medicine
Eli Lilly and Company
GONGCHU Biotechnology Co., Ltd
Sensei Biotherapeutics, Inc.
Gustave Roussy, Cancer Campus, Grand Paris
Tempus AI
Esperas Pharma Inc.